ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series

Overview of attention for article published in Frontiers in Pharmacology, April 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,110 followers.

Thrilled to have this published in #Frontiers as #OpenAccess. This publication highlights some of the mental health AEs our patients have experienced on #tripleTherapy #CFTR #modulators and our centres #doseReduction approach. #kaftrio #trikafta #CF #menta

02 May 2023

Reply Repost Favourite

@3CF_ie

30 Apr 2023

Reply Repost Favourite

New Research: Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series https://t.co/TGqgd0mbSS #pharmacology

27 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.